The financing removes near-term cash runway risk and funds critical Phase 3 catalysts, but the massive dilution will pressure the stock. Watch for the pathological complete response data trigger (≥50 patients) that accelerates Series B warrant expiration, early positive data could reduce overhang. The board designation by Commodore adds activist-like oversight, potentially improving governance.
Drugs in focus
AGEN drug pipeline →botensilimab
◆ Mixed Named in this 8-K- Impact
- Phase
- Phase 3
- Time to market
- At least 3-5 years if Phase 3 BATTMAN succeeds; accelerated approval pathway was denied by FDA
- Next catalyst
- None dated
What to watchAgenus just announced a heavily dilutive ~$85M PIPE at $3.69/share to fund the Phase 3 BATTMAN trial, the stock is likely to trade under pressure from the overhang. Near-term upside depends on Phase 2 data catalysts (ASCO/ESMO presentations) and potential partnership deals, not regulatory approvals. The ~14.4% short interest adds squeeze risk on positive data surprises, but the fundamental path to commercialization is years away.
How the stock moved after the report
BEARISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 13 $6.12entry
- T+1 · 4mo ago −16.99%α −17.35% · $5.08
- T+5 · 4mo ago −18.14%α −17.35% · $5.01
- T+20 · 3mo ago +14.38%α +11.19% · $7.00
- T+60 · 6w ago +22.39%α +18.39% · $7.49
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Agenus entered into a securities purchase agreement for a ~$85M PIPE financing led by Commodore Capital, issuing shares at $3.69 along with Series A ($4.02 strike) and Series B ($5.03 strike) warrants. Proceeds will fund the Phase 3 neoadjuvant trial of botensilimab/balstilimab in colon cancer and extend operating runway through key readouts. The offering is highly dilutive relative to the $140M market cap, but the cash infusion and board designation rights for Commodore provide a governance backstop.
Key Financial Metrics
Key Facts
- ~$85M PIPE priced at $3.69 per share (with warrants), plus pre-funded warrants at $3.68
- Series A warrants exercisable at $4.02; Series B warrants at $5.03
- Series A warrants expire 30 days after 60 patients dosed in Phase 3 colon cancer trial; Series B warrants expire 30 days after pathologic response data for ≥50 patients
- Lead investor Commodore Capital Master LP receives board designation rights (two directors) upon reaching 5% beneficial ownership
- Proceeds used for general corporate purposes and to extend runway through pCR, interim EFS, and final EFS readouts for BOT/BAL in colon cancer
- 90-day lockup on further equity issuance without lead investor consent
- Company to use commercially reasonable efforts to extend $24.75M promissory note maturity with Ocean 1181 LLC
Financial Impact
~$85M gross proceeds; dilution of approximately 61% of pre-offering market cap from shares and pre-funded warrants, with additional potential dilution from Series A and B warrants
Risk Factors
- Significant dilution from the offering and warrants could weigh on share price
- Clinical trial risk: BOT/BAL Phase 3 colon cancer data may fail to meet endpoints
- Potential need for additional financing if trial readouts are delayed or negative
- Warrant overhang: Series A and B warrants could be exercised, adding further dilution
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-301414 |
| Document: d111026dex102.htm | 0001193125-26-301414 |
| Document: d111026dex43.htm | 0001193125-26-301414 |
| Document: d111026dex42.htm | 0001193125-26-301414 |
Track record
12 reports on AGEN
3 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +138.65% at T+60 after the May 11, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $6.35 Now $6.29 −0.94% settles Feb 16
- Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $6.97 Now $6.29 −9.76% settles Feb 12
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $6.44 Now $6.29 −2.33% settles Feb 3
- Aug 12, 202613w ago 8-K Neutral 2/10 Entry $7.00 to $6.90 Now $6.29 −10.14% ▼ −1.43% +3.81% vs SPY
- Aug 12, 202613w ago Institutional Cluster Mixed 4/10 Entry $6.90 to $6.97 Now $6.29 −8.84% ▲ +1.01% +5.89% vs SPY
- Aug 7, 202614w ago S-3 Bearish 7/10 Entry $7.00 to $6.76 Now $6.29 +10.14% ▲ +3.43% +1.53% vs SPY
- Aug 6, 202614w ago 8-K Neutral 5/10 Entry $7.49 to $6.84 Now $6.29 −16.02% ▼ −8.68% −7.01% vs SPY
- Jul 17, 202617w ago S-3 Bearish 5/10 Entry $4.97 to $6.95 Now $6.29 −26.56% ▼ −39.84% −35.00% vs SPY
- Jul 13, 202618w ago 8-K Bearish 6/10 Viewing Entry $6.12 to $7.49 Now $6.29 −2.78% ▼ −22.39% −18.39% vs SPY
- May 13, 202626w ago DEFA14A Neutral 4/10 Entry $3.47 to $6.96 Now $6.29 +81.27% ▲ +100.58% +96.14% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers